Found: 43
Select item for more details and to access through your institution.
Targeted treatment and new agents in peripheral T-cell lymphoma.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 2, p. 192, doi. 10.1001/jamadermatol.2022.5740
- By:
- Publication type:
- Article
Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 11, p. 6669, doi. 10.1007/s00520-021-06241-6
- By:
- Publication type:
- Article
Importance of Early Splenectomy in Patients with Hepatosplenic T-Cell Lymphoma and Severe Thrombocytopenia.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2009, v. 16, n. 7, p. 2014, doi. 10.1245/s10434-009-0470-0
- By:
- Publication type:
- Article
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 3, p. 525, doi. 10.1111/bjh.18885
- By:
- Publication type:
- Article
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 1, p. 54, doi. 10.1111/bjh.18467
- By:
- Publication type:
- Article
Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 2, p. 212, doi. 10.1111/bjh.18052
- By:
- Publication type:
- Article
Pembrolizumab in relapsed or refractory Richter syndrome.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e117, doi. 10.1111/bjh.16762
- By:
- Publication type:
- Article
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B‐cell lymphoma, leg type.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. e79, doi. 10.1111/bjh.16211
- By:
- Publication type:
- Article
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 445, doi. 10.1111/bjh.14333
- By:
- Publication type:
- Article
Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 1, p. 16, doi. 10.1111/bjh.14402
- By:
- Publication type:
- Article
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 1, p. 96, doi. 10.1111/bjh.13400
- By:
- Publication type:
- Article
Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 439, doi. 10.1002/ajh.27165
- By:
- Publication type:
- Article
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1751, doi. 10.1002/ajh.27069
- By:
- Publication type:
- Article
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 1027, doi. 10.1002/ajh.26270
- By:
- Publication type:
- Article
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice: PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 8, p. e83
- By:
- Publication type:
- Article
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 7, p. 74
- By:
- Publication type:
- Article
An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 10, p. 908
- By:
- Publication type:
- Article
Integrative Oncology and the Clinical Care Network: Challenges and Opportunities.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 12, p. 3946, doi. 10.3390/jcm12123946
- By:
- Publication type:
- Article
Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 6, p. 916, doi. 10.1093/bjd/ljae039
- By:
- Publication type:
- Article
Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 2, p. 234, doi. 10.1111/bjd.21063
- By:
- Publication type:
- Article
Long-term follow-up and management of small and medium-sized CD4<sup>+</sup> T cell lymphoma and CD8<sup>+</sup> lymphoid proliferations of acral sites: a multicenter experience.
- Published in:
- International Journal of Dermatology, 2016, v. 55, n. 11, p. 1248, doi. 10.1111/ijd.13340
- By:
- Publication type:
- Article
Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.
- Published in:
- Cancers, 2021, v. 13, n. 22, p. 5854, doi. 10.3390/cancers13225854
- By:
- Publication type:
- Article
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2293, doi. 10.3390/cancers12082293
- By:
- Publication type:
- Article
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
- Published in:
- Investigational New Drugs, 2010, v. 28, p. 58, doi. 10.1007/s10637-010-9591-3
- By:
- Publication type:
- Article
Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
- Published in:
- Photodermatology, Photoimmunology & Photomedicine, 2012, v. 28, n. 5, p. 250, doi. 10.1111/j.1600-0781.2012.00689.x
- By:
- Publication type:
- Article
Letermovir and maribavir for pan‐resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 5, p. 699, doi. 10.1111/jcpt.13585
- By:
- Publication type:
- Article
Romidepsin in the treatment of cutaneous T-cell lymphoma.
- Published in:
- Journal of Blood Medicine, 2011, v. 2, p. 37, doi. 10.2147/JBM.S9649
- By:
- Publication type:
- Article
New Strategies to Optimize Outcomes in Patients With T-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, p. S84, doi. 10.3816/CLML.2010.s.014
- By:
- Publication type:
- Article
Primary cutaneous marginal zone lymphoma treated with doxycycline in a pediatric patient.
- Published in:
- Pediatric Dermatology, 2020, v. 37, n. 4, p. 759, doi. 10.1111/pde.14165
- By:
- Publication type:
- Article
Peripheral T cell lymphoma: clinical utility of romidepsin.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2012, v. 2, p. 109, doi. 10.2147/BLCTT.S22585
- By:
- Publication type:
- Article
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 x 10<sup>9</sup>/L): Final Analysis of an Open-Label Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 336, doi. 10.1016/j.clml.2021.10.016
- By:
- Publication type:
- Article
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Circulating Tumor DNA in Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 6, p. 298, doi. 10.1007/s11899-022-00677-1
- By:
- Publication type:
- Article
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
- Published in:
- Current Hematologic Malignancy Reports, 2020, v. 15, n. 4, p. 333, doi. 10.1007/s11899-020-00583-4
- By:
- Publication type:
- Article
Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 8, p. 929, doi. 10.1002/ajh.25513
- By:
- Publication type:
- Article
Autologous vs Allogeneic Hematopoietic Cell Transplantation for Patients With Peripheral T-cell Lymphomas—Closer, Yet Still So Far to Go.
- Published in:
- 2021
- By:
- Publication type:
- Opinion
Novel therapeutic agents for cutaneous T-Cell lymphoma.
- Published in:
- Journal of Hematology & Oncology, 2012, v. 5, n. 1, p. 24, doi. 10.1186/1756-8722-5-24
- By:
- Publication type:
- Article
An Unusual Extranodal Presentation of Non-Hodgkin Lymphoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2012, v. 10, n. 9, p. 623
- By:
- Publication type:
- Article
A Critical Analysis of Prognostic Factors in North American Patients With Human T-Cell Lymphotropic Virus Type-1-Associated Adult T-Cell Leukemia/Lymphoma.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 14, p. 3438, doi. 10.1002/cncr.25147
- By:
- Publication type:
- Article
Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1150715
- By:
- Publication type:
- Article
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
- Published in:
- Journal of Cachexia, Sarcopenia & Muscle, 2020, v. 11, n. 4, p. 962, doi. 10.1002/jcsm.12570
- By:
- Publication type:
- Article